EIKN (NASDAQ:EIKN) Receives $25.60 Consensus Target Price from Brokerages

EIKN (NASDAQ:EIKN) has received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $25.60.

Several brokerages have commented on EIKN. Mizuho started coverage on shares of EIKN in a research note on Monday. They set an “outperform” rating and a $26.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of EIKN in a research report on Monday. They set an “overweight” rating and a $29.00 target price for the company. Wedbush initiated coverage on EIKN in a research report on Thursday, February 26th. They set an “underperform” rating and a $7.00 price target on the stock. Morgan Stanley started coverage on EIKN in a research note on Monday. They set an “overweight” rating and a $32.00 price objective for the company. Finally, Bank of America initiated coverage on EIKN in a research note on Monday. They issued a “buy” rating and a $34.00 target price on the stock.

EIKN Stock Up 9.9%

EIKN stock opened at $15.16 on Monday. EIKN has a 52 week low of $13.28 and a 52 week high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.